Trajan Scientific and Medical (Trajan) applauds ASTech Deputy Director Prof Emily Hilder, who has been made a Fellow of the Australian Academy of Technology and Engineering.
A pioneer of disruptive approaches to chromatography, microsampling, blood analysis, explosives detection and biopharmaceutical analysis; Prof Hilder has a long history collaborating with Trajan to develop innovative technologies.
She was also the inaugural Director of ASTech, the ARC Training Centre for Portable Analytical Separation Technologies, which was co-founded by Trajan and the University of Tasmania in 2014, with more than 2.1 million funding committed by the Australian Government.
Prof Hilder is an influential leader in analytical chemistry; currently serving as Director of the University of South Australia’s Future Industries Institute (FII), Deputy Director of the ARC Research Hub for Integrated Device for End-user Analysis at Low-levels (IDEAL), and Deputy Director of ASTech.
Trajan's Chief Scientific Officer, Dr Gooley said, "Emily fully deserves her appointment as Fellow of ATSE - she has been an exemplary leader in driving productive collaborations with industry. Trajan continues to benefit from Emily’s vision and leadership with our current research activities at FII and ASTech.”
Learn more about our collaborative approach in this video of Prof Hilder speaking with Trajan's Chief Scientific Officer Dr Andrew Gooley, presented by Prof Tanya Monro, Deputy Vice Chancellor Research and Innovation at University of South Australia.
More videos about industry-academic partnerships can be viewed below, or on our YouTube channel.
ASTech Director Prof Brett Paull said, “This is a well-deserved acknowledgement of Emily’s energy and enthusiasm for collaborative research.”
We congratulate Prof Hilder on this national acknowledgement of her positive impact in science, and look forward to what she achieves next!
ATSE - Academy welcomes new leaders as Fellows
University of South Australia - UniSA’s Future Industries leader made a Fellow of the Australian Academy of Technology and Engineering
Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1244 403 100
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.